Compare AbCellera Biologics Inc (ABCL) vs Bit Digital Inc (BTBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Bit Digital Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Bit Digital Inc trades at $1.66 (market cap $583.11M). The key difference: AbCellera Biologics Inc is far larger — about 4× Bit Digital Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | BTBT | |
|---|---|---|
Market Cap | $2.35B | $583.11M |
Sector | Health | Technology |
52-Week High | $8.12 | $4.22 |
52-Week Low | $2.78 | $1.27 |
Enterprise Value | $1.99B | $872.41M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BTBT trades at $1.74, up 5.45% in the past 24 hours, but faces bearish technical signals with 14 sell indicators. The company reported a net loss of $80.32 million in 2025 with a negative net income margin of -145.45%, though revenue reached $113.56 million. Recent news highlights a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase, signaling strategic moves in AI infrastructure and digital assets.
The outlook remains challenging due to persistent losses and high cash burn, but analyst consensus is 100% buy with potential from strategic investments. Key risks include execution on new ventures, competitive pressures, and reliance on financing amid negative operating cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
